B830045N13Rik Activators
B830045N13Rik Activators encompass a spectrum of chemical compounds that indirectly augment the functional activity of B830045N13Rik through diverse and specific signaling pathways. Forskolin, by raising intracellular cAMP levels, could enhance B830045N13Rik activity by PKA-dependent phosphorylation if B830045N13Rik is a substrate or regulated by PKA. B830045N13Rik Activators are a suite of chemical compounds that indirectly enhance the functional activity of B830045N13Rik through a variety of signaling pathways, each interacting with key regulatory mechanisms. Forskolin, by increasing intracellular cAMP, indirectly activates B830045N13Rik by stimulating PKA, which could phosphorylate and regulate proteins that modulate B830045N13Rik's activity. This cascade effect also involves Sildenafil and Zaprinast, which inhibit cGMP-specific phosphodiesterases, leading to an accumulation of cGMP and cAMP that can further enhance PKA or cGMP-dependent protein kinase activity, potentially impacting B830045N13Rik function. Epigallocatechin gallate, with its inhibitory action on certain protein kinases, may release B830045N13Rik from negative regulatory constraints, while Ionomycin and A23187, by increasing intracellular calcium, can trigger a series of calcium-dependent protein kinase activations that may converge on B830045N13Rik activation. PMA, through PKC activation, and Y-27632, as an inhibitor of ROCK, offer additional routes for indirect enhancement of B830045N13Rik via modulation of phosphorylation events or actin cytoskeleton dynamics, respectively. The activity of B830045N13Rik is further influenced by compounds targeting the PI3K/Akt and MAPK pathways. LY294002, by inhibiting PI3K, could shift cellular signaling in favor of pathways that activate B830045N13Rik, assuming its activity is linked to or regulated by PI3K/Akt dynamics. SB203580 and U0126, through specific inhibition of p38 MAPK and MEK1/2, respectively, may create a signaling environment that favors the activation of B830045N13Rik, particularly if it is subject to suppression by these kinases' activities.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
This polyphenol inhibits several protein kinases, altering signaling pathways. If B830045N13Rik is negatively regulated by any of these kinases, inhibition by Epigallocatechin gallate could remove this suppression, enhancing B830045N13Rik activity. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $76.00 $265.00 | 80 | |
Ionomycin is a calcium ionophore that increases intracellular calcium levels, which could activate calcium-dependent protein kinases that may phosphorylate and activate B830045N13Rik or proteins that modulate B830045N13Rik activity. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA activates protein kinase C (PKC) which, through phosphorylation, can regulate the function of many proteins. If B830045N13Rik is a direct or indirect target of PKC, this would lead to its activation. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $54.00 $128.00 $199.00 $311.00 | 23 | |
A23187 acts as a calcium ionophore similarly to Ionomycin, thus it can indirectly enhance the activity of B830045N13Rik via calcium-dependent signaling pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that may shift signaling pathways towards those that activate B830045N13Rik if B830045N13Rik is part of the PI3K/Akt pathway or if its activity is enhanced by a reduction in PI3K signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that might enhance B830045N13Rik activity by reducing p38 MAPK signaling, which could relieve negative feedback or competitive signaling pathways that suppress B830045N13Rik function. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which may enhance B830045N13Rik activity by lowering the activity of the MAPK/ERK pathway, potentially relieving B830045N13Rik from ERK-mediated inhibition. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $75.00 $212.00 | 18 | |
Rolipram is a selective inhibitor of phosphodiesterase 4, which degrades cAMP. By preventing cAMP breakdown, Rolipram can enhance pathways that use cAMP as a second messenger, potentially leading to the activation of B830045N13Rik. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $103.00 $245.00 | 8 | |
Zaprinast inhibits phosphodiesterases, increasing cGMP levels, which might enhance signaling pathways that could lead to the activation of B830045N13Rik if B830045N13Rik is influenced by cGMP-dependent protein kinases. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is an inhibitor of Rho-associated protein kinase (ROCK), which may enhance B830045N13Rik activity by modulating actin cytoskeleton dynamics, if B830045N13Rik activity is associated with cytoskeletal regulation. | ||||||